ResearchMoz

ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment

GBI Research
Published Date » 2013-04-15
No. Of Pages » N/A
     
  ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment  
   
 GBI Research, the leading business intelligence provider, has released its latest research: “ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment”. The report provides insights into the up-and-coming trends of the ADHD market in seven major markets: the US, the top five European countries (France, Germany, Italy, Spain and the UK) and Japan.  
   
 The report includes market forecasts to 2019, detailed pipeline analysis, in-depth profiling of major products and details of recent industry deals. The report is built using data and information sourced from proprietary...
1 Table of Contents
1.1 List of Figures
1.2 List of Tables

2 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market to 2018 – Executive Summary

3 ADHD Therapeutics Market to 2018 – Introduction
3.1 Etiology and Pathophysiology
3.1.1 Genetic Influences
3.1.2 Environmental Influences
3.1.3 Pathophysiology
3.2 Epidemiology
3.2.1 Child/Adult Subpopulations
3.2.2 Male/Female
3.3 Diagnosis
3.3.1 DSM-IV Criteria for ADHD
3.3.1.1 DSM-V Revision
3.3.2 ICD-10 Criteria for Hyperkinetic Disorder
3.3.3 Diagnostic Rating Scales
3.3.4 Issues with Diagnosis
3.3.5 Co-Morbid Disorders
3.4 Treatment and Management Options
3.4.1 Pharmacologic Treatment
3.5 Drivers and Barriers for ADHD Therapeutics Market
3.5.1 Drivers
3.5.1.1 High Prevalence of ADHD
3.5.1.2 Need for Effective Non-Stimulant Therapies
3.5.2 Barriers
3.5.2.1 Increasingly Competitive Market
3.5.2.2 Social Factors
3.5.2.3 High Level of Co-Morbidity
3.6 Report Guidance

4 ADHD Therapeutics: Market Characterization by Geography
4.1 All Major Markets
4.1.1 Market Size – All Major Markets
4.1.2 Market Forecast – All Major Markets
4.1.3 Annual Cost of Therapy – Average of All Major Markets
4.2 The US
4.2.1 Market Size – The US
4.2.2 Market Forecast - The US
4.2.3 Annual Cost of Therapy – The US
4.3 Top 5 Countries of Europe
4.3.1 Market Size – France
4.3.2 Market Forecast – France
4.3.3 Annual Cost of Therapy – France
4.3.4 Market Size – Germany
4.3.5 Market Forecast – Germany
4.3.6 Annual Cost of Therapy – Germany
4.3.7 Market Size – Italy
4.3.8 Market Forecast – Italy
4.3.9 Annual Cost of Therapy – Italy
4.3.10 Market Size – Spain
4.3.11 Market Forecast – Spain
4.3.12 Annual Cost of Therapy – Spain
4.3.13 Market Size – The UK
4.3.14 Market Forecast – The UK
4.3.15 Average Annual Cost of Therapy – The UK
4.4 Japan
4.4.1 Market Size – Japan
4.4.2 Market Forecast – Japan
4.4.3 Annual Cost of Therapy – Japan

5 ADHD Therapeutics Market to 2018 – Competitive Landscape
5.1 Overview of Major Marketed Products in the ADHD market
5.1.1 Adderall XR (mixed amphetamine salt)
5.1.1.1 Overview
5.1.1.2 Efficacy
5.1.1.3 Safety
5.1.2 Daytrana (methylphenidate transdermal patch)
5.1.2.1 Overview
5.1.2.2 Efficacy
5.1.2.3 Safety
5.1.3 Concerta (methylphenidate hydrochloride)
5.1.3.1 Overview
5.1.3.2 Efficacy
5.1.3.3 Safety
5.1.4 Intuniv (guanfacine)
5.1.4.1 Overview
5.1.4.2 Efficacy
5.1.4.3 Safety
5.1.5 Strattera (atomoxetine hydrochloride)
5.1.5.1 Overview
5.1.5.2 Efficacy
5.1.5.3 Safety
5.1.6 Vyvanse (lisdexamfetamine dimesylate)
5.1.6.1 Overview
5.1.6.2 Efficacy
5.1.6.3 Safety
5.1.7 Kapvay (clonidine hydrochloride)
5.1.7.1 Overview
5.1.7.2 Efficacy
5.1.7.3 Safety
5.1.8 Focalin XR (dexmethylphenidate hydrochloride)
5.1.8.1 Overview
5.1.8.2 Efficacy
5.1.8.3 Safety
5.1.9 Generic products

6 ADHDTherapeutics Market to 2018 – Product Pipeline Analysis
6.1 Introduction
6.2 ADHD Therapeutics Pipeline – Pipeline by Phases of Development
6.3 Trends in the ADHD Therapeutic Pipeline

7 ADHD Therapeutics Market to 2018 – Strategic Consolidations
7.1 Overview
7.1.1 Deals by Deal Type
7.1.2 Deals by Year
7.1.3 Deals by Geography
7.1.4 Deals by Value
7.2 M&A Landscape
7.2.1 M&A Deals by Deal Type
7.2.2 M&A Deals by Year
7.2.3 M&A Deals by Geography
7.2.4 M&A Deals by Deal Value
7.2.5 Sanofi-Aventis Merger, 2004
7.3 R&D Licensing Agreements
7.3.1 Deals by Year
7.3.2 Deals by Geography
7.3.3 Deals by Deals Value
7.3.4 Targacept and AstraZeneca Agreement, 2009
7.4 Co-Development Agreements
7.4.1 Deals by Year
7.4.2 Deals by Geography
7.4.3 Deals by Deal Value
7.4.4 Shire and New River Co-Development Deal, 2005

8 Appendix
8.1 Abbreviations
8.2 Research Methodology
8.2.1 Coverage
8.2.2 Secondary Research
8.2.3 Primary Research
8.2.4 Market Size by Geography
8.3 Geographical Landscape
8.4 Pipeline Analysis
8.5 Competitive Landscape
8.5.1 Expert Panel Validation
8.6 Contact Us
8.7 Disclaimer
8.8 Sources
8.9 Disclaimer

List of Tables

Table 1: DSM-IV criteria for attention deficit hyperactivity disorder
Table 2: CD-10 criteria for hyperkinetic disorders
Table 3: ADHD Therapeutics, Marketed Products Overview, 2012
Table 4: ADHD Therapeutics, Pre-Clinical Pipeline, 2012
Table 5: ADHD Therapeutics, Phase I Pipeline, 2012
Table 6: ADHD Therapeutics, Phase II Pipeline, 2012
Table 7: ADHD Therapeutics, Phase III 2012
Table 8: ADHD Therapeutics – Pipeline Molecules by Mechanism of Action, 2012
Table 9: M&A Deals by Deal Value

List of Figures

Figure 1: ADHD All Major Markets Market Size ($m) 2006-2011
Figure 2: ADHD All Major Markets Market Forecast ($m) 2012-2018
Figure 3: ADHD Annual Cost of Therapy All Markets ($) 2006-2018
Figure 4: ADHD Market Size US ($m) 2006-2011
Figure 5: ADHD Market Forecast US ($m) 2012-2018
Figure 6: ADHD Annual Cost of Therapy The US ($) 2006-2018
Figure 7: ADHD Market Size France ($m) 2006-2011
Figure 8: ADHD Market Forecast France ($m) 2012-2018
Figure 9: ADHD Annual Cost of Therapy France ($) 2006-2018
Figure 10: ADHD Market Size Germany ($m) 2006-2011
Figure 11: ADHD Market Forecast Germany ($m) 2012-2018
Figure 12: ADHD Annual Cost of Therapy Germany ($) 2006-2018
Figure 13: ADHD Market Size Italy ($m) 2006-2011
Figure 14: ADHD Market Forecast Italy ($m) 2012-2018
Figure 15: ADHD Annual Cost of Therapy Italy ($) 2006-2018
Figure 16: ADHD Market Size Spain ($m) 2006-2011
Figure 17: ADHD Market Forecast Spain ($m) 2012-2018
Figure 18: ADHD Annual Cost of Therapy Spain ($) 2006-2018
Figure 19: ADHD Market Size UK ($m) 2006-2011
Figure 20: ADHD Market Forecast UK ($m) 2012-2018
Figure 21: ADHD Annual Cost of Therapy The UK ($) 2006-2018
Figure 22: ADHD Market Size Japan ($m) 2006-2011
Figure 23: ADHD Market Forecast Japan ($m) 2012-2018
Figure 24: ADHD Therapeutics – Pipeline by Phase of Development, 2012
Figure 25: ADHD Therapeutics – Pipeline Molecules by Mechanism of Action, 2012
Figure 26: ADHD Therapeutics – Pipeline by Program Type, 2012
Figure 27: ADHD Therapeutics – Inactive/Discontinued Pipeline Molecules by Target, 2012
Figure 28: Total Deals by Deal Type
Figure 29: Total Deals by Year
Figure 30: Total Deals by Geography
Figure 31: Total Deals by Deal Value
Figure 32: M&A Deals by Deal Type
Figure 33: M&A Deals by Year
Figure 34: M&A Deals by Geography
Figure 35: R&D Licensing Agreements Deals by Year
Figure 36: R&D Licensing Agreements Deals by Geography
Figure 37: R&D Licensing Agreements Deals by DealsValue
Figure 38: Co-Development Agreements Deals by Year
Figure 39: Co-Development Agreements Deals by Geography
Figure 40: Co-Development Agreements Deals by Deal Value
Figure 41: GBI Research Market Forecasting Model

Upcoming Reports:

Predictive Breast Cancer Gene Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Predictive gene testing mentors are used to detect disease or disorder inherited by analyzing gene mutations associated with particular inherited disease or disorder. Predictive gene testing is also known as presymptomatic testing due to the fact that this test is performed even before the early signs of the disease or disorder are observed and thus enable determining person’s risk of suffering disease or disorder.Predictive breast cancer gene testing is performed to identify risk of breast cancer in a person having a family history of breast cancer.  Early...
Respiratory Disease Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018
By - Transparency Market Research
Respiratory diseases are defined as the diseases that affect the nasal passage, air passage, lungs and the bronchi. Respiratory diseases range from acute condition such as common cold, pneumonia, bronchitis to chronic conditions such as chronic pulmonary obstructive diseases (COPD) and asthma. Onset of respiratory infection is provoked by number of causative agent’s namely viral pathogens, bacterial pathogens, smoking, allergens and occupational agents. As cited by World Health Organization (WHO), respiratory disease has become one of the most common causes of deaths...
Blood Disease Treatment Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Blood comprises of red blood cells, white blood cells, plasma and platelets. Sometimes, people might be affected with different types of blood disorders and blood cancers due to aging, infections, exposure to certain chemicals, smoking, genetic disorders and other factors. Hence, the category of blood disorders is wide and numerous types of diseases fall under it. There are three main types of cancer that affect blood namely leukemia which affects the bone marrow and is caused by abnormal production of white blood cells. Myeloma is a type of blood cancer that affects plasma cells whereas...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Ford Motor Co.s Shares Suffer Downfall as Lower Profit Outlook for 2014-2015 Surface
Oct 1, 2014  
Suffering from higher recall costs in its North American market and great losses in South America and Russia have made Ford motor Co. to cut-down its forecast regarding pretax profit this year to $6 billion from $7 billion to $8 billion as earlier mentioned.  Company’s CFO Bob Shanks said that company’s pretax profit in 2015 is expected to rise between $8.5 and $9.5...
Evereadys Kenya Plant to be Shut Down
Sep 30, 2014  
The largest dry-cell battery manufacturer in the region of East Africa, Eveready East Africa Ltd. intends on shutting down its one and only factory in Kenya on the 1st of October 2014. A real estate business will be started in its place. According to the Managing Director of Eveready East Africa Ltd. the plan of shutting down the plant was initiated by the board members of this company...
Sale of Apples iPhones Remains Unaffected - Supported By Consumer Feedback
Sep 29, 2014  
iPhones have been reintroduced in the global market by Apple Inc. in about 22 countries. Consumer reports and feedback basically show that due to the presence of a problem-free backing and update, these handsets are sturdy and do not bend easily. It has been observed via stress tests conducted on iPhone 6 and 6 Plus, that it requires high force and pressure to cause damage to these...
New Malware Targets Pharma Servers
Sep 29, 2014  
The electronics and communication agency Beldon has reportedly spotted a new cyber threat to the pharmaceutical industry. Called Dragonfly, the malware specifically targets intellectual property of servers in the pharmaceutical industry with the purpose of stealing information. An initial report released by ipprolifesciences.com stated the malware was targeting the energy sector....
Child’s Success Depends on Father’s Education Level: Study
Sep 24, 2014  
A father’s level of education is the strongest attribute that can determine a child’s success in academics, according to a research conducted in Britain. It also says that there is a self-reinforcing cycle of lack of achievement and poverty that is handed down from parent to child. The report was released by the Office for National Statistics and states that children are...